DISCLAIMER:This site is not intended to provide medical advice. It is intended to provide infomation from various sources (as referenced), and may take the liberty to format that information in a more understandable way. The presence of any article, book, or document does not imply an endorsement of, or concurrence.
Hovering over words, or phrases, that have a background color will display more information.
Use of vitamin C against prostate cancer
Quick Summaries
1 Calculating a target maintainable plasma concentration.
Comments & Notes
Example Search Arguments
If you click on a list item, you will be directed to "startpage.com" and the search argument will automatically be passed.
You may have to reply to the simple CAPTCHA to continue. It's their way to prevent BOTS from doing massive searches.
Abbreviations
XXXX A1C-Derived Average Glucose
References:
Top
Added May 17 2024:
2015 Apr; Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation
Purpose of this study was to assess the basic kinetic variables in human beings over a relevant AA dosing interval for proper design of future clinical trials.
Ten patients with metastatic prostate cancer were treated for 4 weeks with fixed AA doses of 5, 30 and 60 g.
The target dose of 60 g AA IV produced a peak plasma AA concentration of 20.3 mM.
Elimination half-life was 1.87 hr (mean, S.D. ± 0.40), volume of distribution 0.19 L/kg (S.D. ±0.05) and clearance rate 6.02 L/hr (100 mL/min).
No differences in pharmacokinetic parameters were observed between weeks/doses.
A relatively fast first-order elimination with half-life of about 2 hr makes it impossible to maintain AA concentrations in the potential cytotoxic range after infusion stop in prostate cancer patients with normal kidney function.
Full text of study (free)